Index/Topics/Metastatic Triple-Negative Breast Cancer

Metastatic Triple-Negative Breast Cancer

Cancer type being treated with ivermectin and balstilimab combination

Fact-Checks

5 results

Jan 10, 2026

Which registered clinical trials are testing ivermectin in combination with immune checkpoint inhibitors for cancer and what are their inclusion criteria?

Two registered early‑phase clinical trials combine ivermectin with immune checkpoint inhibitors for cancer: a phase I/II investigator‑initiated trial testing oral ivermectin with balstilimab (and an e...

Jan 7, 2026

What clinical trials have tested ivermectin in combination with chemotherapy in cancer patients, and what were their outcomes?

Clinical testing of ivermectin in cancer patients remains nascent: searches of the clinical literature and trial registries identify essentially one active early-phase trial combining ivermectin with ...

Jan 12, 2026

What published results exist from NCT05318469 (ivermectin + balstilimab) regarding safety and pharmacokinetics?

Published results for NCT05318469 are limited to conference abstracts and trial summaries that report tolerability and early activity signals: an ASCO/Journal of Clinical Oncology abstract states the ...

Jan 7, 2026

Are there ongoing ivermectin cancer trials in specific countries?

There is evidence of a small number of early‑phase clinical trials testing ivermectin in cancer patients, but they are limited in number, mostly based in the United States, and focused on combination ...

Jan 6, 2026

What clinical trials registered in ClinicalTrials.gov are testing ivermectin for cancer as of 2025?

As of 2025, ClinicalTrials.gov shows a single registered interventional study testing ivermectin for cancer: a Phase I/II trial (NCT05318469) combining oral ivermectin with an immune checkpoint inhibi...